[SCHEDULE 13G] Quince Therapeutics, Inc. Passive Investment Disclosure (>5%)
Quince Therapeutics Schedule 13G: 7.2% Reported
Quince Therapeutics, Inc. received a Schedule 13G disclosing that Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report shared beneficial ownership of common stock.
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Quince Therapeutics, Inc. received a Schedule 13G disclosing that Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report shared beneficial ownership of common stock. The filing lists individual shared holdings around 1,403,580–1,403,697 shares, representing 7.2% of the class based on 19,559,257 shares outstanding.
The filing attributes the outstanding-share base to 16,300,740 shares outstanding as of May 4, 2026 plus 3,258,517 shares issued in connection with the Orphai Therapeutics acquisition.
Key Figures
Shares outstanding (used):19,559,257 sharesShares outstanding (as of May 4, 2026):16,300,740 sharesAcquisition-issued shares:3,258,517 shares+3 more
6 metrics
Shares outstanding (used)19,559,257 sharessum of shares as of <date>May 4, 2026</date> and acquisition issuance
Shares outstanding (as of May 4, 2026)16,300,740 sharesreported in issuer's Form 10-Q filed May 11, 2026
Acquisition-issued shares3,258,517 sharesissued in connection with acquisition of Orphai Therapeutics, reported in Form 8-K May 18, 2026
"received a Schedule 13G disclosing that Integrated Core Strategies"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
Shared Dispositive Powerregulatory
"Shared Dispositive Power 1,403,580.00"
Joint Filing Agreementregulatory
"Joint Filing Agreement, dated as of June 9, 2026"
Beneficial Ownershipfinancial
"Amount beneficially owned: See response to Item 9 on each cover page"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Quince Therapeutics (QNCX) is reported by Millennium-related filers?
The filing reports shared beneficial ownership of 7.2% of common stock. This percent is calculated using 19,559,257 shares outstanding derived from the issuer's prior 10-Q and an acquisition issuance.
How many shares does each filer report for QNCX?
The Schedule 13G shows shared holdings of roughly 1,403,580 and 1,403,697 shares among the listed filers. These per-filer counts are reported on the cover pages of the filing.
What outstanding share counts does the QNCX filing use to calculate ownership?
The calculation uses 16,300,740 shares outstanding as of May 4, 2026 plus 3,258,517 shares issued in the Orphai acquisition, totaling 19,559,257 shares for the percent computation.
Who are the parties that jointly filed the Schedule 13G for QNCX?
The joint filers are Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander, per the Joint Filing Agreement dated June 9, 2026.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Quince Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
22053A206
(CUSIP Number)
06/04/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
22053A206
1
Names of Reporting Persons
Integrated Core Strategies (US) LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,403,580.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,403,580.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,403,580.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.2 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
22053A206
1
Names of Reporting Persons
Millennium Management LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,403,697.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,403,697.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,403,697.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.2 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
22053A206
1
Names of Reporting Persons
Millennium Group Management LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,403,697.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,403,697.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,403,697.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.2 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
22053A206
1
Names of Reporting Persons
Israel A. Englander
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,403,697.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,403,697.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,403,697.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.2 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Quince Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
611 Gateway Boulevard, Suite 273, South San Francisco, California 94080
Item 2.
(a)
Name of person filing:
Integrated Core Strategies (US) LLC
Millennium Management LLC
Millennium Group Management LLC
Israel A. Englander
(b)
Address or principal business office or, if none, residence:
Integrated Core Strategies (US) LLC
c/o Millennium Management LLC
399 Park Avenue
New York, New York 10022
Millennium Management LLC
399 Park Avenue
New York, New York 10022
Millennium Group Management LLC
399 Park Avenue
New York, New York 10022
Israel A. Englander
c/o Millennium Management LLC
399 Park Avenue
New York, New York 10022
(c)
Citizenship:
Integrated Core Strategies (US) LLC - Delaware
Millennium Management LLC - Delaware
Millennium Group Management LLC - Delaware
Israel A. Englander - United States
(d)
Title of class of securities:
Common Stock, par value $0.001 per share
(e)
CUSIP Number(s):
22053A206
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
See response to Item 9 on each cover page.
(b)
Percent of class:
See response to Item 11 on each cover page.
The percent of class was calculated based on 19,559,257 shares of Common Stock outstanding, which is the sum of (i) 16,300,740 shares of Common Stock outstanding as of May 4, 2026, as reported in the issuer's Form 10-Q filed with the SEC on May 11, 2026, and (ii) 3,258,517 shares of Common Stock issued in connection with the acquisition of Orphai Therapeutics, LLC, as reported in the issuer's Form 8-K filed with the SEC on May 18, 2026.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See response to Item 5 on each cover page.
(ii) Shared power to vote or to direct the vote:
See response to Item 6 on each cover page.
(iii) Sole power to dispose or to direct the disposition of:
See response to Item 7 on each cover page.
(iv) Shared power to dispose or to direct the disposition of:
See response to Item 8 on each cover page.
The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
See Exhibit I
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Integrated Core Strategies (US) LLC
Signature:
/s/ Gil Raviv
Name/Title:
Gil Raviv, Global General Counsel
Date:
06/09/2026
Millennium Management LLC
Signature:
/s/ Gil Raviv
Name/Title:
Gil Raviv, Global General Counsel
Date:
06/09/2026
Millennium Group Management LLC
Signature:
/s/ Gil Raviv
Name/Title:
Gil Raviv, Global General Counsel
Date:
06/09/2026
Israel A. Englander
Signature:
/s/ Israel A. Englander
Name/Title:
Israel A. Englander
Date:
06/09/2026
Comments accompanying signature: ** INTEGRATED CORE STRATEGIES (US) LLC
By: Integrated Holding Group LP, its Managing Member
By: Millennium Management LLC, its General Partner
Exhibit Information
Exhibit I: Joint Filing Agreement, dated as of June 9, 2026, by and among Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.
